Tetrahydrobiopterin (BH 4 ) is a required cofactor for the enzymatic activity of phenylalanine hydroxylase (PAH) and is synthesized de novo from GTP in several tissues. Heterologous expression of PAH in tissues other than liver is a potential novel therapy for human phenylketonuria that is completely dependent upon BH 4 supply in the PAH-expressing tissue. Previous experiments with liver PAH-deficient transgenic mice that expressed PAH in skeletal muscle demonstrated transient correction of hyperphenylalaninemia only with hourly parenteral BH 4 administration. In this report, the fate of intravenously administered BH 4 is examined. The conclusions are that (1) BH 4 administered intravenously is rapidly taken up by liver and kidney, and (2) uptake of BH 4 into muscle is relatively low. The levels of BH 4 achieved in skeletal muscle following IV injection are only 10% of the amount expected were BH 4 freely and equally distributed across all tissues. The half-life of BH 4 in muscle is approximately 30 min, necessitating repeated injections to maintain muscle BH 4 content sufficient to support phenylalanine hydroxylation. The efficacy of heterologous muscle-directed gene therapy for the treatment of PKU will likely be limited by the BH 4 supply in PAH-expressing muscle.
Introduction
Phenylalanine hydroxylase (PAH, EC 1.14.16.1) deficiency is the most common cause of hyperphenylalaninemia in humans and is one of the most common inborn errors of metabolism (IEM) with an incidence of approximately 1:16,000 live births in the US [1] . PAH is an iron-containing, molecular oxygen-requiring homotetramer that is expressed primarily in liver but also in kidney and pancreas. PAH catalyzes the hydroxylation of phenylalanine to tyrosine, and this reaction requires the participation of the unconjugated pterin cofactor (6R)-L-erythro-5,6,7,8-tetrahydrobiopterin (BH 4 ). BH 4 is synthesized de novo from GTP and is abundant in liver [2] . BH 4 is also required for the activities of the other aromatic amino acid hydroxylases (tryptophan and tyrosine hydroxylases) and types I, II, and III nitric oxide synthases.
Chronic untreated hyperphenylalaninemia causes mental retardation, microcephaly, and seizures. Successful therapy of classical phenylketonuria (PKU) due to inherited PAH deficiency requires the reduction of body phenylalanine levels. Contemporary therapy for PKU is based upon decreasing dietary phenylalanine intake; this special synthetic diet however, is expensive, unpalatable and must be maintained for life. Gene therapy is a promising novel approach to the treatment of PKU (and other IEM) with the goal of permanently restoring PAH expression and eliminating the need for a special diet. Liver is the obvious target organ for gene therapy of PKU, but we propose that circulating phenylalanine may be effectively cleared and the PKU phenotype influenced by PAH expressed in tissues other than liver (so-called heterologous gene therapy). We have previously demonstrated that PAH expression in skeletal muscle can correct hyperphenylalaninemia in Pah enu2 mice, a murine model of human PAH deficiency, if the enzyme is supplied with sufficient BH 4 to support physiologically meaningful phenylalanine hydroxylation [3] . Our conclusion however was that the clinical efficacy of muscle-directed gene therapy for PKU would be limited by an inability to maintain sufficient intramuscular BH 4 supply through exogenous injection. In this paper, we describe experiments, using both in vitro and in vivo approaches, performed to investigate the fate of BH 4 administered to mice. Our preliminary data comparing liver and muscle BH 4 uptake following intravenous BH 4 injection have been presented previously [4] ; these investigations were subsequently repeated and extended to other tissues as reported here. We discovered that the capacity of muscle to take up BH 4 from blood is relatively limited in comparison to liver and that a large portion of injected BH 4 is rapidly excreted through the kidney.
Methods

Animal care
All experiments were reviewed and approved by the OHSU Committee on Animal Care and Use. Mouse colonies were maintained in accordance with current IACUC guidelines. Most experiments were performed with LCRPAH mice, a line of transgenic mice on the 129/Sv background that were developed to investigate PAH expression in erythrogenic bone marrow. Investigations of BH 4 uptake were carried out in these mice during ongoing experiments evaluating the effects of bone marrow PAH expression upon hyperphenylalaninemia [5] . Bone marrow PAH expression should not affect the uptake of BH 4 in other tissues such as liver and muscle. Some control data for biopterin levels in tissues were collected on C57Bl/6J mice. Phenylalanine loading studies were carried out on C57Bl/6J and on Pah enu2 mice, a model of human PKU. Mice were 3-6 months age at the time of the experiments. Standard mouse chow and water were provided ad libitum.
Reagents
BH 4 was purchased from Schircks Laboratories, Jona, Switzerland, stored sealed under liquid nitrogen at )20°C, and dissolved in 1% ascorbic acid just prior to injection. Tissue culture supplies were purchased from Gibco Life Technology, Rockville, MD. Protein concentration was measured using a commercially available bicinchonic acid-based kit (Pierce Chemical, Rockford, IL). All other reagents were of the highest available commercial grade and purity.
BH 4 uptake in cultured primary mouse myotubes
Primary mouse myocytes were isolated from 1-to 5-day-old newborn C57Bl/6J or ICR wild-type mice according to established methods [6] . Myocytes were maintained in an undifferentiated state in 50% F10/50% HamÕs media with 20% fetal bovine serum. To induce fusion and differentiation of the cells, fetal bovine serum was replaced with 10% calf serum in standard media. Numerous multinucleate linear myotubes were typically observed in the plates following 5-7 days on calf serum.
Differentiated myotube cultures were exposed to BH 4 -containing media for varying time periods. Cultured myotubes in 60 mm dishes were first washed with sterile PBS then exposed to 1 ml MEM media containing freshly dissolved BH 4 . The final media BH 4 concentration ranged from 1 to 10 lM. The cultures were then incubated at 37°C until harvest. Prior to cell harvest, an aliquot of BH 4 -containing media was removed from the plate and frozen for later BH 4 analysis. The cells were washed twice with PBS, then lysed in 1 ml of 0.1 M potassium phosphate buffer, pH 7.4, 0.1 M DTT, and 0.1% Triton X-100. Following a 10 min incubation at room temperature, supernatants were collected and frozen at )20°C for later BH 4 analysis. BH 4 content of the cells was expressed relative to total cellular protein in the lysates.
BH 4 or phenylalanine administration to mice
Anesthesia (ketamine/xylazine/promethazine) was administered by intraperitoneal injection prior to BH 4 administration. BH 4 (0.1 lmol BH 4 /gm body weight, total volume ¼ 200-300 ll in 1% ascorbic acid) was injected intravenously via the tail vein. At various time points following BH 4 injection, the mice were euthanized under anesthesia by exsanguination via cardiac puncture, perfused via the left ventricle with phosphatebuffered saline (PBS) and tissue samples were collected. Tissues were also collected from mice injected with only 1% ascorbic acid. All solid tissue samples were weighed and homogenized in five volumes of 50 mM Tris/1 mM EDTA/1 mM DTT, pH 7.4. Supernatants were removed and frozen at )20°C until BH 4 analysis. Whole blood samples were drawn into EDTA-containing Eppendorf tubes and centrifuged to separate the plasma from erythrocytes. Plasma was frozen at )20°C and used as is for BH 4 analysis.
Phenylalanine (1 mg/gm body weight ¼ 6 lmol/gm) was administered by intraperitoneal injection without anesthesia. At various time points following injection, the animals were anesthetized, euthanized by exsanguination via cardiac puncture, and perfused with PBS. Solid tissue samples were homogenized in 10% trichloroacetic acid and centrifuged at 3000g for 10 min at room temperature. Phenylalanine concentration was measured in serum samples and in supernatants of tissue homogenates using a fluorometric method [7] .
Measurement of BH 4 concentration
Total biopterin concentration was analyzed by HPLC according to established methods [2] . The reduction state of biopterin (that is, BH 4 vs. dihydrobiopterin (BH 2 )) in tissues was not evaluated in all samples. For solid tissues, the intracellular BH 4 concentration was estimated by dividing the BH 4 content measured in the supernatant by the wet weight of the tissue sample.
Results
BH 4 uptake in vivo
BH 4 uptake into cultured differentiated primary mouse myotubes was measured over 2 h with culture media BH 4 concentration at 1 or 10 lM. A plot of intracellular BH 4 content vs. time for cultures with 10 lM BH 4 in the culture media is presented in Fig. 1 . The amount of intracellular BH 4 increased linearly over the first 10 min then stabilized. No further significant increase in BH 4 uptake was seen over the remainder of the experiment. This result suggests that intracellular and extracellular BH 4 concentration had reached equilibrium and that no further uptake occurred after 10 mins. These data likely do not support an active transport model given that BH 4 uptake does not continue to increase against the intracellular/extracellular gradient. BH 4 uptake was not saturated at least up to an extracellular concentration ¼ 10 lM, five times the normal plasma BH 4 concentration.
Previous investigators have suggested that BH 4 uptake occurs only by passive diffusion [8] . Although our in vitro data do not suggest a transporter-mediated model in cultured myotubes and are consistent with passive diffusion, we can estimate the capacity of the sarcolemma to allow BH 4 uptake by assuming a first order kinetic relationship between extracellular BH 4 concentration and the rate of BH 4 intake into the cells. Creation of a Lineweaver-Burke type plot (not shown) of 1/velocity of BH 4 uptake vs. 1/BH 4 concentration yields a crude K transport ¼ 15 lM and V max ¼ 4:7 pmol/ mg protein/min. In comparison, measurement of neutral amino acid uptake into cultured cells, which is known to occur via sodium-independent facilitated transport (reviewed in Shotwell et al. [9] ), yields K m ¼ 1:3-1.8 mM and V max ¼ 7000-20,000 pmol/mg protein/min [10] .
Native BH 4 supply
Previous measurements by other laboratories of native tissue biopterin content in rats [2] and mice [11] demonstrated the highest biopterin levels in pineal gland, pituitary gland, liver, adrenal gland, spleen, bone marrow, and whole blood with negligible amounts in other tissues including kidney and muscle. Prior to performing IV BH 4 injections, we sought to confirm these results in select tissues from mice in our colony. Tissues were harvested from wild-type mice for measurement of tissue biopterin concentration (Fig. 2) . In agreement with the previously published data, biopterin was abundant in liver of our mice; much less biopterin was present natively in kidney, plasma or skeletal muscle.
BH 4 uptake in vivo
To study tissue uptake of BH 4 from the circulation, BH 4 (0.1 lmol/gm body weight in 1% ascorbic acid) was injected into mice via the tail vein. Animals were euthanized at various time points following injection for analysis of tissue biopterin concentration (Fig. 3) . Plasma biopterin levels increased from approximately 1.5 lM to almost 600 lM immediately postinjection. Biopterin was rapidly cleared from plasma with kinetics that approximate a single compartment pharmacologic model with exponential decay (y ¼ 211e À0:0481x , R 2 ¼ 0:938) (Fig. 3A) . The half-life of biopterin in plasma was only 14.4 min. Were BH 4 freely distributed throughout all tissues and not immediately excreted, then based upon the dose of BH 4 given and the estimated weight of total body water, the maximal BH 4 concentration in any tissue should have been approximately 150 lM. Yet, BH 4 concentration approached 450 lM in kidney, 200 lM in liver, but only 40 lM in skeletal muscle. We also measured erythrocyte biopterin content in a subset of ten animals following IV BH 4 injection; erythocyte biopterin increased from a mean preinjection concentration of 7.0 lM (range ¼ 2.2-12.0 lM, n ¼ 4) up to 1200 lM immediately after injection as measured in a single animal. At subsequent time points and again measured in single animals, erythrocyte biopterin content decreased, down to 150 lM at 120 min postinjection, but always remained greater than the plasma biopterin. Correlation between plasma and erythrocyte BH 4 content has been previously reported [12] .
The half-life of BH 4 in muscle was approximately 30 min. Because the HPLC method used measures total biopterin including the oxidized form of BH 4 , namely 7,8-dihydrobiopterin, the relatively rapid disappearance of biopterin suggests actual movement of BH 4 back out of muscle rather than loss through oxidation. These data indicated significantly lower uptake of BH 4 into muscle in comparison to liver or kidney.
In comparison to BH 4 uptake, phenylalanine transport into muscle is much more robust (Fig. 4A) . Following intraperitoneal injection into wild-type mice, phenylalanine is rapidly taken up by muscle and liver; tissue phenylalanine levels then gradually decrease over 120 min. The serum phenylalanine level remains elevated (normal ¼ 100-150 lM) during this time period. We propose that after the first 30 min following injection, phenylalanine, which had rapidly distributed throughout the body, is transported back into blood and flows to the liver for metabolism. As the total body load is gradually cleared by the liver, the serum phenylalanine level begins to fall. In PAH-deficient Pah enu2 =Pah enu2 mice (Fig. 4B) , phenylalanine injection yields much higher tissue phenylalanine content because liver lacks the capability to metabolize the phenylalanine load. The liver and muscle phenylalanine content parallel each other suggesting that the distribution of phenylalanine is equal between the two tissues.
Discussion BH 4 is a required cofactor for phenylalanine hydroxylase (PAH) activity. One mole of BH 4 is oxidized for each mole of phenylalanine that is hydroxylated to tyrosine. In liver, the supply of BH 4 is maintained both through recycling of qBH 2 back to BH 4 via pterin-4a-carbinolamine dehydratase (EC 4.2.1.96) and dihydropteridine reductase (DHPR) (EC 1.6.99.7) activity and through de novo synthesis of BH 4 from GTP. In any liver-directed gene therapy protocol for PKU, the BH 4 content of liver should be sufficient to support meaningful phenylalanine hydroxylation once PAH activity is expressed within hepatocytes. PAH expressed in other tissues such as muscle will not enjoy such a robust BH 4 supply. The success of heterologous gene therapy for PKU using PAH is dependent upon BH 4 supply to the target tissue. We have previously demonstrated reduced serum phenylalanine levels in muscle PAH-expressing, liver PAH-deficient mice when BH 4 is administered repetitively and in large amounts [3] . The goal of the experiments presented here was to further our understanding of the fate of exogenously administered BH 4 . To our knowledge, this study also represents the first attempt to directly measure BH 4 uptake into skeletal muscle following IV injection.
BH 4 is administered clinically to individuals with BH 4 deficiency secondary to inborn errors of pterin synthesis or recycling. This medical use has stimulated the pharmacologic investigation of parenterally administered BH 4 . For instance, penetration of BH 4 across the blood-brain barrier following IV injection has been shown to be low [13] . In another study, the fate of intravenous 2-14 C-BH 4 was examined in rats by whole body autoradiography [14] . At 4 h following BH 4 injection, the majority of radioactivity was detected in liver, renal cortex, and renal medulla. By 16 h, most radiolabel was retained in liver. Very little radiolabel was detected in skeletal muscle. A similar pattern of radiolabel distribution has been reported following IV injection of 2-14 C-BH 4 into mice [15] . To our knowledge, the tissue distribution of intravenously administered BH 4 in humans has not been systematically studied, however, oral administration of BH 4 yields substantial accumulation of biopterin in urine within 4 h [16] .
The results of our experiments demonstrate that the majority of injected BH 4 is taken up by liver and kidney. Urine biopterin content in a single mouse following IV BH 4 injection was very elevated. Although we did not systematically evaluate urinary biopterin excretion in these animals, we propose that a large fraction of injected BH 4 is rapidly filtered and excreted by the kidney. Much less BH 4 is taken up by skeletal muscle. The muscle BH 4 level is generally only about 5% of the plasma BH 4 concentration following IV BH 4 injection. In contrast, the tissue phenylalanine concentration achieved following phenylalanine injection is much closer to the plasma phenylalanine level at all time points. Following injection, the half-life of muscle biopterin content is short, approximately 30 min. In our previous work, hourly intraperitoneal administration of 0.1 lmol BH 4 /gm body weight was required to support physiologically meaningful phenylalanine hydroxylation in muscle PAH-expressing mice. Under this regimen, plasma BH 4 levels peak at approximately 800 lM but decline to 50 lM by 60 min following injection. Muscle BH 4 never exceeded 5 lM following IP BH 4 administration. After IV injection, muscle BH 4 peaked at approximately 30 lM 5 min after injection but then rapidly declined. The K m for BH 4 in native rat liver phenylalanine hydroxylase is 2 lM [17] . Therefore, muscle BH 4 levels have either met, in the case of IP BH 4 injection, or exceeded (IV injection) the enzyme K m for BH 4 and therefore would be expected to support physiologically significant phenylalanine hydroxylation. However, the required muscle BH 4 level was not sustained; muscle BH 4 content dropped rapidly with a half-life of approximately 30 min. Even following IV injection, the muscle BH 4 content fell below 2 lM by 2 h postinjection. BH 4 uptake across mammalian cell membranes is thought to occur via passive diffusion [8] . Uptake into pheochromocytoma PC12 cells and rat brain synaptosomes is non-saturable, concentration-dependent, and does not require either NaCl or glucose. There is no published evidence for a specific BH 4 transporter in these neuronal cell types or any other mammalian tissue. However, a putative high affinity biopterin transporter, distinct from the folate transporter, has been described in the trypanosome Leishmania tarentolae [18] . The fact that BH 4 in blood is rapidly taken up by mouse liver while muscle uptake is limited suggests the possibility that the mechanism of BH 4 uptake might differ among different tissues. Further investigation into the mechanism of BH 4 uptake into liver will be necessary to fully explain the tissue specific differences we found.
The results of these experiments suggest that multiple repeated BH 4 injections would be required to sustain physiologically significant phenylalanine hydroxylation in animals with muscle PAH expression and explains why hourly intraperitoneal BH 4 injection was necessary to lower serum phenylalanine levels in our muscle PAHexpressing transgenic mice [3] . The efficacy of muscledirected, PAH-mediated gene therapy for the treatment of PKU will be limited unless a method to insure continuous, sufficient intramuscular BH 4 supply is developed. Expression of BH 4 synthetic enzymes, including GTP cyclohydrolase (GTPCH) and 6-pyruvoyltetrahydropterin synthase (PTPS), in cultured fibroblasts yields BH 4 production [19] and phenylalanine hydroxylation in cultured fibroblasts has been demonstrated following retrovirus-mediated expression of PAH along with GTPCH and PTPS [20] . Perhaps, muscle coexpression of PAH, GTPCH, and PTPS via a multicistronic vector would yield sufficient PAH activity and BH 4 supply to support physiologically significant phenylalanine hydroxylation. Alternatively, muscle expression of a cofactor independent, phenylalanine-metabolizing enzyme such as yeast phenylalanine ammonia lyase (PAL, EC 4.3.1.5) [21] could potentially clear circulating phenylalanine and avoid cofactor delivery problems altogether.
